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Objectives: The purpose of this study was to develop clinical decision support systems (CDSS) that are integrated with hospi-
tal information systems for the differential diagnosis of idiopathic pulmonary fibrosis (IPF). Methods: The integrated CDSS 
were validated and evaluated by physicians. Knowledge modeling for diagnosing IPF was performed by knowledge working 
groups, composed of radiologists and respiratory specialists. In order to develop the model for CDSS diagnosis, the clinical 
cases were collected from 290 cases from Seoul National University Hospital and Sevrance Hospital of Yonsei University. For 
the evaluation of integrated CDSS, interviews were conducted with respiratory specialists and radiologist 2 weeks after ap-
plying CDSSs in clinical settings. The CDSS was integrated with the computer vision system (CVS) and diffuse parenchymal 
lung diseases (DPLD), CDSS developed in our previous project. Results: Eighteen cases diagnosed as IPF were applied to the 
collection of diagnostic knowledge and the refined knowledge, the former diagnosed 1 case (6%) and the latter diagnosed 14 
cases (78%). Therefore, the refined knowledge performed better than collected knowledge. The validation results of integrat-
ed CDSSs showed that 81 cases (74.3%) were diagnosed correctly. Conclusions: There were 109 cases of IPF diagnosed and 
initiated on treatment. The significance of this study is in developing integrated CDSS with PACS by acquiring and redefining 
the knowledge needed for IPF diagnosis. In addition, it is significant for the integration of CDSS to verification and clinical 
evaluation.
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I. Introduction
Pulmonary studies have reported that diffuse parenchymal 
lung diseases (DPLD) account for around 130-180 disorders 
of the lung tissue affecting the lung parenchyma, often with 
very nonspecific symptoms [1,2]. Demedts et al. [3] reported 
that the prevalence of idiopathic pulmonary fibrosis (IPF) 
ranges from 6 to about 14 per 100,000 person-years, and the 
incidence of IPF reaches to 175 cases per 100,000 person-
years in those aged 70 years or older. Thus, its importance is 
increasing in Korea as the society ages.
  Interstitial lung diseases (ILD) refer to a group of diseases 
that invade the interstitial tissues of the lung, excluding 
malignant tumors and infections. ILDs invade not only the 
interstitial but also noninterstitial tissues, such as the trachea 
and pulmonary artery, and therefore are often called “dif-
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fuse parenchymal lung diseases (DPLD)” or “infiltrative lung 
diseases (ILD).” DPLD is increasingly used as a generic term 
for these disorders, in preference to terms such as interstitial 
lung disease or diffuse lung disease [4]. The joint statement 
of the American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) defines IPF, the most common of 
several idiopathic interstitial pneumonias (IIPs) in DPLDs, 
as a specific form of chronic fibrosing interstitial pneumo-
nia, limited to the lung, that is progressive and usually fatal 
and unresponsive to treatment [5]. It is a specific entity with 
the histopathological pattern of usual interstitial pneumonia 
(UIP) on surgical lung biopsy [6] and a median survival of 
3 years [7]. Clinical IPF indicates relatively undesirable cat-
amnesis and is recognized as a distinct clinical disorder from 
other DPLDs. 
  Within the IIPs, it is important to distinguish between IPF 
and the other interstitial pneumonias. The importance of a 
detailed differentiation of IPF from other IIPs has been dem-
onstrated by Drent et al. [8]. IPF can be distinguished from 
other forms of DPLD by clinical presentation, lung function 
test, high-resolution computed tomography (HRCT) find-
ings, chest radiology features, laboratory studies, and pathol-
ogy. Precise and correct diagnosis for the degree of inflam-
mation and fibrosis of IPF is important for prognosis and 
treatment, but many of the diseases are rare, and establishing 
a differential diagnosis for ILD is considered difficult [2]. 
Due to the difficulties in the differential diagnosis in terms 
of clinical approach, diagnostic uncertainty, and philosophy 
between IPF and nonspecific interstitial pneumonia (NSIP), 
previous clinical reports on IPF must be considered care-
fully. It is difficult even for respiratory specialists to decide to 
what extent examinations should be undertaken. 
  However, physicians only performing physical examina-
tions often fail to make a correct diagnosis and prescribe 
curative methods for DPLDs, as it is hard distinguish these 
from other lung diseases, such as pulmonary tuberculosis or 
chronic obstructive pulmonary disease (COPD), including 
chronic bronchial infection, emphysema, and symptoms by 
aging. The American Thoracic Society/European Respiratory 
Society (ATS/ERS) consensus statement [9] described the 
major and minor criteria for the clinical diagnosis of IPF as 
developed from expert opinion in the absence of a surgical 
lung biopsy. It includes HRCT and bronchoaveolar lavage 
(BAL) among the 4 major criteria, and increases the likeli-
hood of a correct clinical diagnosis of IPF [10]. If patients 
do not meet these major and minor criteria, the respiratory 
physician should be directed to perform a surgical lung bi-
opsy [3,5,11]. Table 1 shows the major and minor criteria for 
the clinical diagnosis of IPF from the ATS/ERS consensus 
statement. 
  Physical examination of a patient in DPLDs is frequently 
abnormal, but with nonspecific and differential findings. In 
Korea, the prevalence rate of DPLDs is deemed to be high, 
although no accurate values have been reported because of 
the difficulties in differential diagnosis among the DPLD 
groups in primary care. 
  We performed knowledge modeling for the diagnosis of 
IPFs through knowledge working groups composed of respi-
ratory specialists and radiologists. For knowledge modeling 
in this study, diagnosis knowledge acquisition, refining, and 
representing were performed iteratively. The knowledge was 
acquired from all resources, including pulmonary disease 
guidelines and physicians’ experience. For the knowledge 
refining process, acquired knowledge was applied to clinical 
Table 1. American Thoracic Society/European Respiratory Society (ATS/ETS) criteria for diagnosis of idiopathic pulmonary fibrosis in 
the absence of surgical lung biopsy [3,11]
Major criteria
Exclusion of other known causes of interstitial lung disease such as certain drug toxicities, environmental exposures,
    and connective tissue diseases
 Abnormal pulmonary function studies that include evidence of restriction and/or  impaired gas exchange 
 Bibasilar reticular abnormalities with minimal ground-glass opacitie on high-resolution computed tomography scans
Transbronchial biopsy or bronchoaveolar lavage showing no features to support an alternative diagnosis
Minor criteria
 Age > 50 yr
 Insidious onset of otherwise unexplained dyspnoea on exertion
 Duration of illness > 3 mo
 Bibasilar, inspiratory crackles (dry or velcro rales type in quality)262 doi: 10.4258/hir.2010.16.4.260  www.e-hir.org
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cases and analyzed by the chi-square test. The refined knowl-
edge was represented with IF-THEN rules for the inference 
engine of the integrated clinical decision support systems 
(CDSSs) developed in this study. 
  Meanwhile, integrating a medical database with an expert 
system improves the knowledge base construction and CDSS 
performance. Yet, the IT environment is still heterogeneous 
and most of the diagnostic systems have been developed as 
stand-alone systems. This has been considered a major im-
pediment to knowledge acquisition for CDSSs. Knowledge 
acquisition directly from the database through the interface 
mechanism is often of considerable value to CDSS quality 
management [12]. The efficiency and quality of the CDSSs 
could increase when medical instruments, such as the labo-
ratory interpretation system, electrocardiogram, electroen-
cephalogram, magnetic resonance imaging, and HRCT, are 
integrated with them. Medical instruments are indispensable 
to the practice of medicine and essential to correct diagnosis. 
Integrated medical instruments that have internal computers 
containing the CDSSs are not difficult to use with current 
interfacing technology. 
  In this study, the IPF CDSS linked with the Picture Archi-
ving Communication System (PACS) automatically ac-
quires the interpretation and radiological diagnosis results 
of HRCT through the computer vision system (CVS) and 
DPLD CDSS. The DPLD CDSS integrated with the CVS was 
developed and evaluated in our previous study [13]. The 
CVS automatically interprets ground-glass opacities (GGOs) 
and honeycombing, some of the main HRCT image find-
ings required to diagnose IPF. The DPLD CDSS deduces 
the information necessary for diagnosing 12 DPLD-related 
diseases, using the image findings automatically interpreted 
by the CVS. The CVS calls the HRCT images, containing 
the image files transmitted from the PACS, from the direc-
tory and begins image detection of the lesions of the GGOs 
and honeycombing. A digital imaging and communications 
in medicine (DICOM ) [1] data file is composed of names, 
gender, and various associated patient data necessary to the 
CDSSs. In reading such DICOM files, the information is 
put into the knowledge base used in the CDSS. Data ware-
housing has been proved as being an efficient and effective 
information supply from heterogeneous systems in much 
previous research and many technical reviews [14,15]. We 
attempted to integrate all of the patient information in the 
hospital information systems by constructing a data ware-
house.
  The purpose of this study is to acquire knowledge from 
HRCT images for diagnosing DPLD and knowledge from 
knowledge working groups for diagnosing IPF, and to devel-
op an IPF CDSS integrated with other hospital information 
systems and DPLD CDSSs [16] to make accurate differential 
diagnoses between IPF and NSIP. In addition, the study was 
designed to enhance feasibility by applying systems to real 
clinical settings and physician evaluations. 
II. Methods
1. Collecting Clinical Cases
In this study, the clinical and radiological screening diag-
nosis of IPF was subjected to system development. Two 
hundred ninety cases were diagnosed as DPLDs or IPFs and 
treated from December 2002 to February 2008 at Seoul Na-
tional University Hospital and Yonsei University Hospital. 
One hundred nine of these patients (Seoul National Univer-
sity Hospital, 7; Yonsei University Hospital, 102) who suf-
ficiently underwent diagnostic examination were included in 
the study. Among the patients whose diseases were not defi-
nitely diagnosed histologically, those having heart or renal 
failure that might influence radiological or clinical findings 
and those having other pulmonary diseases (lung cancer, 
chronic obstructive pulmonary disease) were excluded from 
this study. 
2. Diagnostic Knowledge Acquisition from Working 
Groups
Expert knowledge on IPF diagnosis was acquired by con-
ducting interviews with respiratory specialists, radiologists, 
medical domain engineers, and system developers at regular 
group meetings. Knowledge modeling began with collecting 
knowledge from various pulmonary disease guidelines. The 
knowledge working group collected and defined diagnostic 
knowledge for DPLD and IPF, based on clinical experiences 
and medical records, through periodic study meetings. Si-
multaneously, websites, journals, and textbooks were studied 
with the intent to acquire up-to-date data and knowledge. 
  To refine the collected knowledge, we added and veri-
fied respiratory physicians’ experience and clinical practice 
knowledge and applied it to the IPF CDSS diagnosis rules. 
These rules were applied to confirmed cases for validation. 
The differences shown in the respective disease groups were 
statistically analyzed by the chi-square test, and the informa-
tion that showed a statistical significance was given clinical 
significance on the basis of respiratory specialist experience 
and knowledge. Rules recognized for providing clinically 
meaningful differences, which had been verified for validity 
based on clinically confirmed cases, were aligned with the 
actual diagnosis process and expressed in IF-THEN form 
for each stage of the process, according to the information 263 Vol. 16  •  No. 4  •  December 2010 www.e-hir.org
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acquisition time and method and importance of the differ-
entiation priority. 
  Since the defined knowledge was designed to focus on in-
creasing discrimination power, it was built by including as 
many patients as possible with the disease in the initial stage 
of the system, and thereafter excluding cases showing a clear 
decrease in possibility. The reasoning method consisted of 
repeatedly narrowing the range of target diseases with each 
condition added to the entire range of diseases, until the fi-
nal diagnosis was reached. 
  In this study, however, we did not include surgical lung 
biopsy results in the diagnosis process of the IPF CDSS. If a 
final decision could not be made using other major and mi-
nor criteria testing results, the IPF CDSS would recommend 
a surgical lung biopsy as the next test procedure and physi-
cians would carefully make a decision based on the patient’s 
state.
  The knowledge base was reconstructed by rearranging the 
knowledge collected and arranged in that base. The final 
diagnosis was made after information for diagnosing DPLD 
and IPF was acquired through the patient’s medical history, 
pulmonary examination, radiological examination, BAL, and 
lung biopsy. As it was difficult to extract from the examina-
tion reports, the “insidious onset of otherwise unexplained 
dyspnea on exertion” was excluded from the criteria. A com-
prehensive knowledge base was rebuilt, which included the 
clinical and image findings required for the IPF diagnosis 
standard as presented by the joint statement of the ATS/ERS 
[3,11] and IPF diagnosis presented by Hunninghake et al. 
[17]. 
3. Integrating CDSSs with PACS
The data warehouse we constructed functions as an inte-
grated hospital information system that potentializes the fi-
nal clinical diagnosis and HRCT diagnosis. Figure 1 presents 
the integration architecture of 2 CDSSs and other hospital 
information systems, including PACS, using the CVS and 
data warehouse. The data warehouse in Figure 1 consists of 
HRCT image data from PACS, patient clinical information, 
patient physical examination results, and laboratory test 
results. The data mart could be handled with multidimen-
sional online analytical processing (OLAP), being linked 
with the database of HRCT data and knowledge base of the 
CDSSs for DPLD and IPF diagnosis. It processes various and 
complicated queries requested by CDSSs. We used Microsoft 
SQL Server 2000 to develop the data warehouse and Micro-
soft Analysis Services to analyze the clinical data from the 
order communication system (OCS), laboratory information 
system (LIS), and other hospital information systems.
  The DPLD CDSS integrated with the CVS was developed in 
our previous project and deduced diagnosis from 12 DPLD 
disease classifications [13]. The IPF CDSS helps respiratory 
specialists to diagnose IPF by using collected patient infor-
mation from the data warehouse integrating hospital infor-
mation systems. The interface and inference engine for the 
IPF CDSS was developed using .NET with the Visual Web 
Developer 2005 express edition and extensible markup lan-
guage (XML), web standard language. 
  We developed an optional function to integrate the IPF 
CDSS with the CVS. In clinical practice, a respiratory physi-
Figure 1. The architecture of two integrated CDSSs using a data warehouse. CDSS: clinical decision support systems, GGO: ground-
glass opacities, DPLD: diffuse parenchymal lung diseases, PACS: picture archiving and communication system, LIS: labora-
tory information system, OCS: order communication system, PFT: pulmonary function tests, DPLD-CDSS: CDSS for radiologi-
cal diagnosis on DPLD [13], CVS: computer vision system extracting GGO, HRCT: high-resolution computed tomography.264 doi: 10.4258/hir.2010.16.4.260  www.e-hir.org
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cian makes a diagnosis with the help of a radiologistp the 
CS, using the a comprehensive knowledge base was rebuilt, 
which included tth automatic HRCT interpretation results 
from the CVS. The respiratory physician can access the in-
formation from the CVS.
III. Results
1. Collecting and Defining Diagnosis Knowledge for IPF
Expert knowledge regarding IPF diagnosis was acquired by 
holding interviews with respiratory specialists, radiologists, 
medical domain engineers, and system developers at regular 
group meetings. 
  IPF, also termed cryptogenic fibrosing aveolitis (CFA) in 
Europe [18], is a distinct and specific form of chronic fibros-
ing interstitial pneumonia with no known cause. The ATS/
ERS revision of the classification of DPLD [11] established 
the guidelines for the classification of IIPs, distinguishing be-
tween IPF and other IIPs [1]. Since they have a clinical simi-
larity but their clinical courses and responses to therapy are 
different, the diagnostic process in patients with suspected 
DPLD begins by making the distinction between idiopathic 
and nonidiopathic diseases. For example, the diagnosis of 
sarcoidosis needs a compatible clinical picture of a systemic 
disease, histological demonstration of noncaseating granulo-
mas, and exclusion of other diseases capable of producing a 
similar histological or clinical picture [19].
  The common clinical feature of IPF is insidious progres-
sive shortness of breath or dyspnea for at least 3-4 months 
[5,11]. Cough and minimal or no sputum is a general feature 
of IIPs. The presence of clubbing on physical examination 
is helpful in suggesting a diagnosis of IPF and pulmonary 
fibrosis associated with rheumatoid arthritis, asbestosis, or 
fibrosing NSIP [18]. A thorough clinical diagnostic approach 
begins with a detailed medical history, physical exam, PFTs, 
chest x-ray, lung function studies, blood tests, and tissue 
analysis [5,11]. An important goal of these multidisciplinary 
clinical approaches is the early diagnosis of the disease, 
which is enhanced by diagnostic agreement [16,20]. 
  If clinical findings fail to suggest an alternative diagnosis, 
HRCT image findings should be obtained [21]. HRCT scan-
ning has greatly improved the ability to visualize and char-
acterize abnormalities in IPF. Extensive reticulation, traction 
bronchiectasis, honeycombing cysts, a subpleural predomi-
nance, and a somewhat patchy distribution are strongly sug-
gestive of HRCT findings in IPF. The appearance of GGOs 
on HRCT is not characteristic of IPF [5]. Therefore, HRCT 
allows the clinician to make the distinction between “possible 
IPF” and “non-IPF” [5,18]. Hunninghake et al. have sug-
gested that relatively accurate clinical and radiologic data, 
interpreted by an experienced pulmonologist or radiologist, 
are sufficient to diagnose IPF, precluding and even obviating 
the need for a lung biopsy [10,18]. 
  Transbronchial biopsy (TBBx) and BAL have limited use 
as diagnostic tools, but are sufficient to help exclude other 
causes of pulmonary interstitial infiltrates, such as sarcoid-
osis, hypersensitivity pneumonitis, malignant disease, and 
infection, when surgical biopsy is not an option [5]. A recent 
article in Chest [19] suggested that the TBBx may have some 
utility with well-defined criteria. Berbescu et al. [21] exam-
ined TBBx samples from 22 UIP patients. 
  Restrictive pulmonary physiology is the classic finding on 
pulmonary function testing in IPF [20,22]. There is impaired 
gas transfer reflected in a decrease in carbon monoxide dif-
fusion in the lung (DLCO) and alveolar oxygen partial pres-
sure (PaO2), which is associated with increased mortality 
[18,23]. An increase in oxygen desaturation on exercise is 
well correlated with the extent of disease on HRCT. There 
may be hypoxemia with an increased alveolar-arterial O2 gra-
dient (A-aPO2). In addition, although the typical findings of 
pulmonary function tests (PFTs) in IPF are consistent with 
restrictive impairment, PFTs or arterial blood gases (ABGs) 
may be normal. Typical findings of airway restriction include 
a decreased forced vital capacity (FVC) and total lung capac-
ity (TLC) and DLco [3,5,11]. 
  The presence of typical findings on clinical and radiologic 
examination may allow for a confident diagnosis, precluding 
the need for a surgical lung biopsy. A surgical lung biopsy 
in suspected IPF remains the gold standard for diagnosis, 
but it can be limited to those patients who show an atypical 
pattern, such as a predominant lymphocytosis on HRCT or 
in BAL, or an atypical clinical presentation, such as young 
age or short duration of illness. The surgical lung biopsy 
should be carefully considered and performed on the bases 
of HRCT findings [5].
  In this study, we did not include surgical lung biopsy results 
in the IPF CDSS diagnostic process since the diagnosis of 
the CDSS focused on differentiating IPF from other DPLDs 
in primary care. Instead, the IPF CDSS recommends surgical 
lung biopsy as the next test procedure, and that physicians 
make a careful decision according to the patient’s state.
2. Refining Diagnosis Knowledge for IPF
  For knowledge redefinition, we added verified respiratory 
physicians’ experience and clinical practice knowledge to 
the IPF CDSS diagnosis rules. The collected knowledge was 
applied to cases of confirmed diagnosis for validation. The 
information that showed a statistical significance was given 265 Vol. 16  •  No. 4  •  December 2010 www.e-hir.org
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clinical significance on the basis of the respiratory specialists’ 
experience and knowledge.
  The collected knowledge based on major and minor criteria 
for the clinical diagnosis of IPF suggested by the joint state-
ment of the ATS/ERS guidelines [3,11] and HRCT image 
findings for IPF diagnosis suggested by Hunninghake et al. 
[17,24] was refined and redefined. The differences shown 
in each DPLD group were statistically analyzed by the chi-
square test, which was applied to differentiate IPF from other 
DPLD groups unrelated to connective tissue disease (CTD). 
In this analysis, we excluded an unexplained insidious dys-
pnea because it is currently difficult to acquire such cases.
  For the first step, to differentiate IPF from CTD unrelated 
to other DPLD groups [2], the 18 IPF cases confirmed by 
diagnosis through surgical biopsy were compared with the 
10 cases of other DPLD groups confirmed clinically (Table 2). 
The characteristics of these 2 diseases are apparently differ-
ent in a population. 
  The different clinical findings between IPF and other DPLD 
disease groups were analyzed by the chi-square test. A p-
value lower than 0.05 was considered statistically significant. 
The results (Appendixes 1 and 2) show that, among the clini-
cal features, dyspnea on exertion (DOE) (IPF, 77.8%; other 
DPLDs unrelated to CTD, 30.3%; p < 0.05), duration from 
the beginning of having symptoms to visiting clinics (IPF, 
more than 14 days; other DPLDs unrelated to CTD, less than 
12 days), and the presence of Velcro rale (IPF, 72.2%; other 
DPLDs unrelated to CTD, 20.2%; p < 0.05) were apparently 
different between IPF diseases and other DPLDs unrelated 
to CTD. The radiologic findings analyzed by the chi-square 
test demonstrate that consolidation, traction bronchiecta-
sis, GGO, lower location of honeycombing, and subpleural 
lesions were significantly different between IPF and other 
DPLDs unrelated to CTD (p < 0.05) (Appendix 3). 
  To differentiate IPF from other DPLDs related to CTD, 
however, the 18 IPF cases confirmed with the diagnosis of 
surgical biopsy were compared to 10 cases of other DPLDs 
related to CTD (Appendixes 4 and 5). The characteristics of 
these 2 diseases have similarities in radiological diagnosis, 
but are apparently distinguished by clinical features and 
prognosis by a secondary cause of DPLD. The different clini-
cal findings between IPF and other DPLDs related to CTD 
were analyzed by the chi-square test. A p-value lower than 
0.05 was considered statistically significant. The different 
clinical findings between IPF and other DPLDs related to 
CTD were analyzed by the chi-square test. The results (Ap-
pendix 6) show that among the clinical features, ex-smoker 
(IPF, 11.1%; DPLDs related to CTD, 0.0%; p < 0.05), cough 
(IPF, 88.9%; DPLDs related to CTD, 10.0%; p < 0.05), DOE 
(IPF, 77.8%; DPLDs related to CTD, 40.0%; p < 0.05), weight 
loss (IPF, 11.1%; DPLDs related to CTD, 0.0%; p < 0.05), and 
the presence of Velcro rales (IPF, 72.2%; DPLDs related to 
CTD, 30.0%; p < 0.05) were apparently different between IPF 
diseases and other DPLDs related to CTD. The radiologic 
findings analyzed by the chi-square test (p < 0.05) show that 
consolidation, traction bronchiectasis, GGO, lower location 
of honeycombing, and subpleural lesions were significantly 
different between IPF and other DPLDs related to CTD (Ap-
pendix 7).
  When the collected knowledge from guidelines such as the 
joint statement of the ATS/ERS and refined knowledge by 
statistical analysis were applied to 18 cases confirmed as IPF, 
the former diagnosed 1 case (6%) and the latter diagnosed 
14 cases (78%). If traction bronchiectasis, one of the HRCT 
image findings, was removed from the diagnosis rules, the 
diagnosis performance of the collected knowledge was en-
hanced by 6 cases (33%). In addition, when the collected 
knowledge from guidelines such as the joint statement of the 
ATS/ERS and refined knowledge by statistical analysis were 
applied to 11 cases under medical treatment, the former di-
agnosed 1 case (9%) and the latter diagnosed 7 cases (64%). 
If traction bronchiectasis, one of the HRCT image findings, 
was removed from the diagnosis rules, the diagnosis perfor-
mance of the collected knowledge was enhanced by 3 cases 
(27%). Therefore, refined knowledge performed better than 
collected knowledge.
Table 2. Characteristics of subjects
Variables
Idiopathic pulmonary 
fibrosis (n = 18)
Other DPLDs unrelated 
to CTD
a) (n = 10)
Sex Male 11 (61.1) 7 (70)
Female 7 (38.9) 3 (30)
Age 60.3 ± 8.9 64.4 ± 6.8
Mode 64 68
Median 61 63
Values are presented as number (%) or mean ± SD.
DPLD: diffuse parenchymal lung disease, CTD: connective tis-
sue disease. 
a)Other DPLDs include nonspecific interstitial pneumonia 
(NSIP), desquamative interstitial pneumonia (DIP), respiratory 
bronchiolitis–associated interstitial lung disease (RBILD), acute 
interstitial pneumonia (AIP), cryptogenic organizing pneumo-
nia (COP), and lymphocytic interstitial pneumonia (LIP).266 doi: 10.4258/hir.2010.16.4.260  www.e-hir.org
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3. Representing Diagnosis Knowledge for IPF
The 3 diagnosis steps for IPF were extracted from refined 
knowledge. Figure 2 shows the flow chart of these steps, 
which we refined from the respiratory physicians’ experience 
and clinical practice knowledge. 
  As the order of priority of the 3 steps was not provided in 
IPF diagnosis research literature, the order of priority in 
the diagnosis process was designed based on the empirical 
knowledge of experts verified by clinical trials at the redefi-
nition stage of this research, and was reflected in the diagno-
sis process of CDSS.
  Step 1 is the step for confirming the presence of clinical 
features. When the program is run by calling a patient’s 
clinical information from the data warehouse through the 
data interface forms or with the manual input of informa-
tion, and if, based on that basic clinical information, there 
is a chance of IPF, the clinician proceeds to the next step. If 
the likelihood of IPF is small, clinical information enhance-
ment or PFT implementation is recommended. After the 
PFT result is input into the system, the next process is sug-
gested based on the result. In step 2, the step diagnosing 
radiological features, the HRCT image findings and reading 
results are automatically received as direct input from the 
DPLD CDSS and CVS. From the DPLD CDSS, the diagnosis 
results confirmed by the radiologist are received as text. For 
high-level users able to read the information, in addition to 
the text reading option, direct image examination is made 
available as a diagnostic reference. When the clinical infor-
mation and radiological information are ready, the likeli-
hood of IPF is analyzed and the physician either modifies 
the information or proceeds to the next step. Step 3, the step 
diagnosing the presence of CTD-related DPLDs, after select-
ing the target group with a high likelihood of IPF, confirms 
the CTD-related DPLDs in order to eliminate the possibil-
ity of other associated diseases. Verification of antinuclear 
antibodies (ANAs) and rheumatoid factors, the markers for 
CTDs, is strictly enforced, and proceeding to the next step 
is allowed only after the physician confirms whether there 
are any associated CTDs present. Step 4, the diagnosis step 
to eliminate the presence of other associated diseases, as in 
cases of CTDs, eliminates cases of important associated lung 
diseases that are expected to bring substantial change to the 
prognosis and treatment guidelines. If lymphocytosis (in 
terms of the BAL differential count, lymphocyte > 15%) is 
shown from BAL, even if it clinically falls under IPF, the user 
is shown other diseases so that they can also be considered. 
Since the likelihood of IPF decreases for people under the 
age of 50 years, the user is given the opportunity to consider 
other associated diseases. The likelihood of IPF as the final 
inferred diagnosis result is presented for the data, which has 
been confirmed by the user in a conversation form. For the 
CDSS inference application, the knowledge is expressed with 
IF-THEN rules.
4. Developing IPF CDSS and Integrating with DPLD CDSS
Patient clinical information from the OCS, past diagnos-
tic information, physical and laboratory test information, 
HRCT image information, and knowledge and experience 
based on inquiry are needed in order for respiratory special-
ists to clinically diagnose IPF. Thus, hospital information 
systems should be integrated so that such diagnostic pro-
cesses, as well as the process of knowledge acquisition, can 
be implemented in the system. 
  The diagnosis process of the IPF CDSS developed in this 
study is as follows (Figure 3). When the IPF CDSS program 
is started, a patient case list, which already exists in the data 
warehouse, appears on the CDSS. On clicking a patient 
name or number in the list, all laboratory examinations from 
the data warehouse, including clinical information and the 
diagnosis results from the DPLD CDSS of the given patient, 
are read into the IPF CDSS and displayed on the screen. The 
input of the confirmed diagnosis result among the 12 diseas-
es from the DPLD CDSS, based on the image interpretation 
Figure 2. The flowchart on diagnosis of idopathics pulmonary 
fibrosis (IPF). DOE: dyspnoea on exertion, D: duration, 
PFT: pulmonary function test, HC: honey combing, Sub: 
subpleural location predominancy, No cons: absence 
of consolidation, GGO: ground glass opacity, CTD: con-
nective tissue disease, ANA: antinuclear antibodies, RF: 
rheumatoid factor, BAL: bronchoaveolar lavage.267 Vol. 16  •  No. 4  •  December 2010 www.e-hir.org
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from the CVS, are both automatically and directly made. 
  If an examination required for IPF diagnosis is missing, the 
program recommends the given examination, carries out the 
diagnosis when all the information needed for that diagnosis 
has been input, and presents the diagnosis confirmation for 
the physician to review. If making the final diagnosis is diffi-
cult based on the given result, the system gives the physician 
the option to recommend surgical lung biopsy, based on the 
patient’s condition.
5. Validation and Evaluation of CDSSs
IPF CDSS validation was implemented. First, the IPF diag-
nosis algorithm validation was implemented for the filtering 
process to express the diagnosis knowledge as a rule.
  To verify the validity of the IPF diagnosis algorithm, 290 
histological confirmation cases of DPLDs were collected for 
validation of the diagnosis rules and algorithms for 3 years 
(2005. 2.-2008. 2.) from Seoul National University Hospi-
tal and Severance Hospital in Yonsei University. The cases 
included HRCT image data, clinical laboratory test results, 
patient physical test results, and lung biopsy results. Out of 
the 109 cases that were critically diagnosed as IPF and being 
treated, 81 (74.3%) were diagnosed as IPF by the IPF CDSS. 
Likewise, the IPF CDSS was applied to the 28 cases that were 
diagnosed as other DPLDs. As a result, there were no cases 
where other diseases had been diagnosed as IPF (Table 3). 
  Meanwhile, validity analysis of the CVS-integrated CDSS 
was implemented with 10 patient cases diagnosed as IPF. 
The system detected 100% honeycombing from the HRCT 
images of the 10 patient cases, and the CDSS using the IPF 
diagnosis rules showed an accuracy rate of 98%. Considering 
such results, the IPF CDSS developed in this study, with its 
accurate IPF diagnosis decision-making, is considered able 
to aid in the quality of diagnosis. 
  For the evaluation of the CDSS, the DPLD CDSS was set in 
a clinical environment. Five radiologists at Seoul National 
University Hospital and 2 respiratory physicians at Yonsei 
University Hospital were educated to use the CDSS program, 
and evaluated the system usability. The evaluation of de-
monstrative operation was analyzed. When ascertaining the 




IPF 81 (74.3) 0 (0.0)   81
Non-IPF 28 (25.7) 181 (100.0) 209
Total 109 181 290
Values are presented as number (%).
IPF: idiopathic pulmonary fibrosis, CDSS: clinical decision sup-
port systems.
Figure 3. The idopathics pulmonary fibrosis (IPF) clinical decision support systems (CDSS) screen. Patient’s information for diagnosis 
on IPF are extracted from the datawherehouse and presented on the CDSS screen. The buttons on screen; SAVE: save the all 
of patient clinical information from datawarehouse, HRCT results: a physician is able to evaluate the radiological findings 
resulted from CVS radiology diagnosis consolidation, GGO, traction bronchiectasis, subpleural location historical features & 
physical findings. C.C.: chief complaint, DOE: dyspnoea on exertion, Velcro: velcro rales, PFTs: pulmonary function standards 
for tests, ANA: antinuclear antibodies, FVC: forced vital capacity, FEV: forced expiratory volume, BAL: bronchoalveolar la-
vage; surgical lung biopsy, TBLB Bx: transbronchial biopsy, BAL Bx: bronchoalveolar lavage biopsy.268 doi: 10.4258/hir.2010.16.4.260  www.e-hir.org
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precision of diagnosis, the automatic image detection of the 
CVS and radiologists’ gross examination indicated a consen-
taneity of about 99%. 
  A questionnaire was conducted on user satisfaction, quali-
tative improvement, and proposals, among other things, to 
examine the outcomes after clinical experiment. The users 
mostly felt that the CDSS would be of help to diagnose dis-
eases and most of them were satisfied with the results. Many 
users suggested that HRCT findings should be classified as to 
meaning rather than presented in alphabetical order. Surveys 
and system use evaluations will be regularly collected and 
reflected iteratively for system modification, enhancement, 
and improvement to increase the accuracy and efficiency of 
diagnosis.
IV. Discussion
  The significance of this study is in developing the CDSS 
by acquiring and redefining the knowledge needed for IPF 
diagnosis. This study undertook knowledge modeling of the 
knowledge needed for IPF diagnosis, based on study of the 
literature, respiratory specialists’ experience, and analysis of 
confirmed cases, stored the defined knowledge in a knowl-
edge base, and expressed the knowledge with IF-THEN 
rules. To derive the new diagnostic rules for IPF diagnosis, 
knowledge modeling was done through a process consisting 
of knowledge collection, knowledge refining and redefining, 
and knowledge representation. First, the knowledge working 
group, through a study of the literature, compiled the knowl-
edge for understanding the individual data sets needed for 
differential diagnosis, such as the location and duration 
of the disease, symptoms and indications, and various ex-
amination results. For knowledge refining and redefining, 
the differences between each data set’s disease groups were 
statistically analyzed through a chi-square test, and for each 
data set showing statistically meaningful differences, clini-
cal significance was assigned based on the experience and 
knowledge of a respiratory specialist.
  The CVS-integrated DPLD CDSS was integrated with the 
IPF CDSS developed in this study, and the automatic analy-
sis results of the image data were automatically received as 
direct input. The HRCT image of PACS directly received as 
input from the CVS were GGO and honeycombing opinions. 
The algorithm allowed the next step when 2 of the 4 criteria 
were satisfied. It was also significant in terms of integrating 
the CDSSs, which were verified and evaluated by the clinical 
demonstration.
  If forecasting power can be improved through knowledge 
base supplementation, it is hoped that, for limited situations, 
this will develop into a basis for treatment. In such cases, the 
latest knowledge and experience related to the treatment and 
control of relevant diseases must be offered together in some 
way. This advancement requires the appropriate manage-
ment of a histologically confirmed case database, and since 
this is needed to derive more elaborate diagnosis rules in the 
future, it is recommended that the recognition of new data 
be regularly confirmed by respiratory specialists and this 
process be managed separately. 
  In this study, new images were received during the demon-
stration period and used to validate the prospective results 
of the system. By validating the usability and convenience of 
the system, this study demonstrates that it can be set up and 
expanded from the demonstration run for full implementa-
tion. By directly applying the developed system in a clinical 
environment, it was possible to measure its actual utility in 
terms of accuracy, convenience, and usability for diagnosis 
decision-making of radiologists and respiratory specialists. 
This paper is part of a larger ongoing study. The demonstra-
tion run period will be extended to iteratively and regularly 
check the accuracy of diagnosis and demands of end-users, 
and the results will be reflected in system improvements. 
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Appendix 1. Clinical features (1) 
IPF (n = 18)
Other DPLDs unrelated 
to CTD (n = 10)
History
Chief complaint
Dyspnea 10 (55.6) 7 (70.0)
Cough   8 (44.4) 3 (30.0)
Duration
a 14.3 ± 16.0 7.6 ± 12.3
Smoking
Non smoker   2 (11.1) 4 (40.0)
Ex-smoker 11 (61.1) 2 (20.0)
Current smoker   5 (27.8) 4 (40.0)
Smoking amount 15.3 ± 17.4 21.3 ± 26.5
Symptom
Fever 0 (0.0) 2 (20.0)
Cough 16 (88.9) 9 (90.0)
Sputum 11 (61.1) 7 (70.0)
Dyspnoea 11 (61.1) 7 (70.0)
DOE
a  14 (77.8) 3 (30.0)
Hemoptysis 0 (0.0)               0 (0.0)




Presence 13 (72.2) 2 (20.0)
Absence   5 (27.8) 8 (80.0)
Values are presented as mean ± standard deviation for duration, 
smoking amountor number (%). 
DPLD: diffuse parenchymal lung disease, IPF: idiopathic pul-
monary fibrosis, DOE: dyspnoea on exertion.
ap < 0.05. 
Appendix 2. Clinical features (2) 
IPF (n = 18)
Other DPLDs 
unrelated to CTD 
(n = 10)
PFT (%)
FEV1  77.8 ± 23.1 64.0 ± 24.5
FVC    69.5 ± 19.0 57.8 ± 21.8
DLco   59.8 ± 17.2 32
Restrictive pattern 5/13 (38.5) 3/6 (50.0)
Arterial blood gas
PaO2   84.9 ± 25.9   74.4 ± 12.3
PaCO2  43.5 ± 18.2 34.8 ± 4.9
Values are presented as mean ± SD or number (%). 
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease, PFT: pulmonary 
function test, FVC: forced vital capacity, FEV: forced expiratory 
volume, DLco: diffusing capacity of the lung for carbon mon-
oxide, DLco test involves measuring the partial pressure differ-
ence between inspired and expired carbon monoxide, PaCO2: 
amount of O2 in arterial blood, PaCO2: amount of CO2 in arte-
rial blood.
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Appendix 3. Radiologic findings 
IPF (n = 18)
Other DPLDs 




None 16 (88.9) 3 (30.0)
Upper 0 (0.0) 1 (10.0)
Lower 2 (11.1) 2 (20.0)
Upper & mid 0 (0.0) 1 (10.0)
Whole 0 (0.0) 3 (30.0)
Ground glass opacity
a
None 9 (50.0) 4 (40.0)
Lower 9 (5.00) 2 (20.0)
Upper & mid 0 (0.0) 1 (10.0)
Whole 0 (0.0) 3 (30.0)
Traction bronchiectasis
None 16 (88.9) 9 (90.0)
Lower   2 (11.1) 1 (10.0)
Honey combing
a
None   2 (11.1) 10 (100.0)
Lower 14 (77.8) 0 (0.0)
Whole   2 (11.1) 0 (0.0)
Emphysema
None 14 (77.8) 9 (90.0)
Upper   3 (16.7) 1 (10.0)
Whole 1 (5.6) 0 (0.0)
Lymphadenopathy
Presence   9 (50.0) 5 (50.0)
Absence   9 (50.0) 5 50.0)
Subpleural lesion
a
Yes 16 (88.9) 1 (10.0)
No   2 (11.1) 9 90.0)
Values are presented as number (%).
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease.  
ap < 0.05.
Appendix 4. Characteristics of subjects
IPF (n = 18)
Other DPLDs 
related to CTD 
(n = 10)
Sex Male 11 (61.1) 2 (20.0)
Female   7 (38.9) 8 (80.0)
Age   60.3 ± 8.9 50.6 ± 15.2
Values are presented as number (%) or mean ± SD.
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease.   
Appendix 5. Clinical features (1) 
IPF (n = 18)
Other DPLDs related 
to CTD (n = 10)
History
Chief complaint
Dyspnea 10 (55.6) 7 (70.0)
Cough   8 (44.4) 3 (30.0)
Duration 14.3 ± 16.0 13.3 ± 18.7
Smoking
a 
Non-smoker   2 (11.1) 1 (10.0)
Ex-smoker 11 (61.1)            0 (0.0)
Current smoker   5 (27.8) 9 (90.0)
Smoking amount 15.3 ± 17.4 3.0 ± 9.5
Symptom
Fever 0  1 (10.0)
Cough
a 16 (88.9) 4 (40.0) 
Sputum 11 (61.1) 5 (50.0)
Dyspnoea 11 (61.1) 4 (40.0)
D.O.E.
a 14 (77.8) 2 (20.0)
Hemoptysis 0 (0.0)            0 (0.0)
Weight loss




Presence 13 (72.2) 3 (30.0)
Absence   5 (27.8) 7 (70.0)
Values are presented as number (%) or mean ± SD.
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease, D.O.E.: dyspnoea 
on exertion.
aIndicates significance differences of p < 0.05.272 doi: 10.4258/hir.2010.16.4.260  www.e-hir.org
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Appendix 6. Clinical features (2) 
IPF (n = 18)
Other DPLDs related 
to CTD (n = 10)
PFT (%)
FEV1  77.8 ± 23.1 64.0 ± 24.5
FVC  69.5 ± 19.0 78.3 ± 20.8
DLco  59.8 ± 17.2 74.6 ± 29.6
Restrictive pattern 5/13 (38.5) 4/8 (50.0)
Arterial blood gas
PaO2 84.9 ± 25.9 95.9 ± 18.8
PaCO2 43.5 ± 18.2 38.0 ± 3.8
Values are presented as mean ± standard deviation. 
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease, PFT: pulmonary 
function test, FVC: forced vital capacity, FEV: forced expiratory 
volume, DLco: diffusing capacity of the lung for carbon mon-
oxide, DLco test involves measuring the partial pressure differ-
ence between inspired and expired carbon monoxide, PaCO2: 
amount of O2 in arterial blood, PaCO2: amount of CO2 in arte-
rial blood.
aIndicates significance differences of p < 0.05.
Appendix 7. Radiologic findings 
IPF (n = 18)
Other DPLDs 




None 16 (88.9) 8 (80.0)
Upper 0 (0.0) 1 (10.0)
Lower 2 (11.1) 0 (0.0)
Mid & lower 0 (0.0) 1 (10.0)
GGO
a
None 9 (50.0) 5 (50.0)
Lower 9 (50.0) 3 (30.0)
Upper  0 (0.0) 1 (10.0)
Whole 0 (0.0) 1 (10.0)
Traction bronchiectasis
None 16 (88.9) 7 (70.0)
Lower 2 (11.1) 3 (30.0)
Honey combing 
None 2 (11.1) 4 (40.0)
Lower 14 (77.8)  6 (60.0)
Whole 2 (11.1) 0 (0.0)
Emphysema
None 14 (77.8)  10 (100.0)
Upper 3 (16.7) 0 (0.0)
Whole 1 (5.6) 0 (0.0)
Lymphadenopathy
Presence 9 (50.0) 2 (20.0)
Absence 9 (50.0) 8 (80.0)
Subpleural lesion
Yes 16 (88.9) 8 (80.0)
No  2 (11.1) 2 (20.0)
Values are presented as number (%).
IPF: idiopathic pulmonary fibrosis, DPLD: diffuse parenchymal 
lung disease, CTD: connective tissue disease, GGO: ground 
glass opacity.
ap < 0.05. 